

Company

March 13, 2023

DANGCEM

Strong Q4 Performance Supports Earnings

Top-line Climbs Despite Macroeconomic Headwinds

Strong Q4 performance supports Dangote Cement Plc's (DANGCEM) earnings in 2022FY despite the decline in profitability witnessed in 9M:2022. Expansion in revenue amidst lower volumes, robust cost reduction strategy (especially in Q4 were Nigeria EBITDA improved 37.01% QoQ), strengthened its earnings per share (EPS) to NGN22.27 in 2022FY (vs. NGN21.24 in 2021FY).

DANGCEM yet again delivered an impressive top-line performance (+16.96% YoY to NGN1.61trn) despite the various macroeconomic headwinds that plagued the firm during the year. The growth was driven by increased price realization as implied cement price per ton was higher (from NGN53,374.11 in 2021 to NGN67,563.53 in 2022). Meanwhile, the group recorded a reduction in sales volume by 5.14% YoY to 27.77MT as both its Nigeria and Pan African volumes declined by 4.14% YoY and 8.05% YoY respectively. Specifically, the slightly lower volume, which reflected the high base of 2021, significant rise in inflation, and energy supply disruptions (due to low gas generation) impaired DANGCEM's ability to maximize production in 2022. Furthermore, extended plant maintenance in Senegal and Congo and volatility in cement and clinker landing costs in Cameroon, Ghana and Sierra Leone impacted sales volumes from its Pan-African businesses. Nevertheless, the successful implementation of its national consumer promotion (Bag of Goodies Season 3) in Q3:2022 which improved its market share and extended into Q4:2022 where the firm recorded stronger revenue (19.46% QoQ) supported overall performance. For 2023, we remain optimistic about the firm's topline performance premised on increase in local demand, and reduction in energy disruptions which lowered volumes in 2022. Specifically, we expect cement demand to be sustained by increasing housing infrastructure and commercial construction as well as the increase in exporting activities. Thus, we estimate a revenue growth of 15.50% YoY.


Cost Savings Initiative and Reduction in Tax Props Bottom-line

The combined effect of increase in cost of sales (+20.30% YoY) and spike in operating expenses (+46.52% YoY) weakened the firm's EBITDA margin to 43.76% (vs. 49.48% in 2021). The rise in production costs - particularly energy (+35.52% YoY) which mirrored the inflationary environment (increase in Automotive Gas Oil prices) and jump in haulage expense (+64.38% YoY) pressured **DANGCEM**'s total cost during the period. However, the firm implemented a cost reduction strategy which involved the increased use of alternative fuel to improve their energy mix and the use of Compressed Natural Gas (CNG) for trucks given the rising AGO cost. The effect of this cost reduction initiative resulted in improved EBITDA position in Q4:2022 (+34.78% QoQ) and EBITDA margin of 43.61%. Consequently, despite the spike in total finance costs (98.41% YoY) with foreign exchange (FX) losses (+515.21% YoY) constituting the bulk of the cost, after-tax-profit came in higher (+4.90% YoY to NGN382.31bn) in 2022. Also, reduction in tax expense (from NGN173.92bn in 2021 to NGN141.69bn in 2022) due to reversals of temporary differences from deferred taxes further strengthened bottom-line. We project a 10.88% YoY growth in net income for 2023FY. This is based on the expected expansion in revenue, sustained innovative use of alternative fuel system to minimize cost and management's effort to mitigate its FX challenges.

Recommendation

Based on our revised projections, we forecast an EBITDA per share of NGN50.75 and an EV/EBITDA of 6.54x. Hence, we arrived at our target price of NGN331.91, which implies an upside of 19.37% from the closing share price on 10th March 2022. Thus, we rate the ticker a "BUY".

31.32
63.32
9.20x
4.55x
6.54x
50.75
331.91
278.00
+19.37%
BUY
49.46%
20.40%
32.98%
0.62x
2.42x
288.00
261.00
+10.34%
0.85
0.89
17.04bn
4.06trn
December
2022FY



Analyst
Samuel Banmeke
samuelbanmeke@meristemng.com
(+234 818 518 2859)



March 13, 2023

Chart 1: Sensitivity Analysis

Sensitivity Analysis of Dec-2022 Target Price to key model inputs								280.70
	EBITDA per share						Max	339.21
	299.15	42.92	43.36	50.75	44.31	44.82	_	
	6.67	286.31	289.25	338.54	295.58	298.99	_	
T+ 51//50ITD A	6.61	283.50	286.41	335.22	292.69	296.05		
Target EV/EBITDA	6.54	280.70	283.57	331.91	289.79	293.12		
	6.61	283.78	286.69	335.56	292.98	296.35		
	6.68	286.87	289.81	339.21	296.16	299.57	_	

Financial Highlights and Forecasts (NGN billion)						
Profit & Loss Account	2021FY	2022FY	2023F	2024F	2025F	2026F
Revenue	1,383.56	1,618.32	1,975.58	2,133.14	2,344.74	2,586.29
Cost of sales	475.07	572.13	(724.30)	(780.29)	(870.37)	(950.08)
Gross Profit	908.49	1,046.19	2,699.87	2,913.43	3,215.12	3,536.36
OPEX	231.20	345.48	360.95	390.86	445.17	478.52
Other Income	6.22	5.33	10.47	11.34	12.02	13.92
EBITDA	683.51	706.04	864.81	957.59	1,018.09	1,141.30
Net Finance Cost	44.94	91.66	23.14	32.34	45.98	66.59
PBT	538.37	524.00	605.55	710.71	738.14	827.07
PAT	364.44	382.31	423.89	497.50	516.70	578.95

Balance Sheet	2021FY	2022FY	2023F	2024F	2025F	2026F
Property, Plant and Equipment	1,472.86	1,527.29	1,547.14	1,782.54	2,025.89	2,285.79
Total Debt	564.94	706.73	425.68	463.07	533.58	612.73
Total Assets	2,392.02	2,615.66	2,223.36	2,551.28	2,863.52	3,243.21
Total Equity	983.67	1,078.95	945.97	1,029.04	1,185.73	1,361.62
Total Current Liabilities	1,076.48	1,021.69	920.42	1,111.01	1,220.08	1,370.27
Non-Current Liabilities	331.87	515.02	356.97	411.22	457.71	511.32
Total Liabilities	1,408.35	1,536.71	1,277.40	1,522.23	1,677.79	1,881.59

Financial Ratios	2021FY	2022FY	2023F	2024F	2025F	2026F
Gross Margin	65.66%	64.65%	136.66%	136.58%	137.12%	136.74%
EBITDA Margin	49.40%	43.63%	43.77%	44.89%	43.42%	44.13%
Net Margin	26.34%	23.62%	21.46%	23.32%	22.04%	22.39%
Return on Asset	15.24%	14.62%	19.07%	19.50%	18.04%	17.85%
Return on Equity	37.05%	35.43%	44.81%	48.35%	43.58%	42.52%
Return on Invested Capital	23.10%	32.59%	28.43%	29.72%	28.62%	26.17%
Earnings Per Share	21.39	22.44	24.88	29.20	30.32	33.97
Asset Turnover	0.58x	0.62x	0.89x	0.84x	0.82x	0.80x
Financial Leverage	2.43x	2.42x	2.35x	2.48x	2.41x	2.38x
Debt to Asset Ratio	23.62%	27.02%	19.15%	18.15%	18.63%	18.89%
Debt to EBITDA Ratio	82.65%	100.10%	49.22%	48.36%	52.41%	53.69%
Current Ratio	66.30%	96.56%	58.17%	52.25%	51.92%	53.50%
Quick Ratio	53.25%	76.03%	37.74%	30.82%	30.89%	32.61%



March 13, 2022

Contact Information

	Brokerage and Retail Services topeoludimu@meristemng.com contact@meristemng.com	(+234 905 569 0627)	
	Investment Banking/Corporate Finance rasakisalawu@meristemng.com seunlijofi@meristemng.com	(+234 806 022 9889) (+234 808 536 5766)	
	Wealth Management funmilolaadekola-daramola@meristemng.com crmwealth@meristemng.com Tel: +234 01 738 9948	(+234 805 498 4522)	
	Registrars oluseyiowoturo@meristemregistrars.com www.meristemregistrars.com Tel: +23401-280 9250	(+234 802 321 0561)	
	Trust Services damilolahassan@meristemng.com trustees@meristemng.com	(+234 803 613 9123)	
	Group Business Development sulaimonadedokun@mersitemng.com ifeomaogalue@meristemng.com info@meristemng.com	(+234 803 301 3331) (+234 802 394 2967)	
	Client Services adefemitaiwo@meristemng.com car@meristemng.com	(+234 803 694 3034)	
	Finance olasokomubo@meristemfinance.com matthewawotundun@meristemfinance.com	(+234 803 324 7996) (+234 802 390 6249)	
	Investment Research damilareojo@meristemng.com praiseihansekhien@meristemng.com research@meristemng.com	(+234 816 890 2771) (+234 817 007 1512)	
~			

Corporate websites: www.meristemng.com www.meris

Meristem Research can also be accessed on the following platforms:

Meristem Research portal: meristem.com.ng/rhub

Bloomberg: MERI <GO>

Capital IQ: www.capitaliq.com Reuters: www.thomsonreuters.com

ISI Emerging Markets: www.securities.com/ch.html?pc=NG FactSet: www.factset.com

Analyst's Certification and Disclaimer



March 13, 2022

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

- (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and
- (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.
- (3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

Analysts' Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

Investment Ratings

Fair Value Estimate

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

Target Price Estimate

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

Ratings Specification

BUY: Target Price of the stock is above the current market price by at least 10 percent

HOLD: Target Price of the stock ranges between **-10 percent and 10 percent** from the current market price.

SELL: Target Price of the stock is more than **10 percent** below the current market price.

NGX: DANGCEM I Bloomberg: DANGCEM NL EQUITY I Reuters: DANGCEM.LG



March 13, 2022

Definitions

Price Targets: Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.

Asset allocation: The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.

Movements in Price Target

Company Name: Dangote Cement Plc.

Date	Price (N)	Previous Target Price(N)	New Target Price (N)	Previous Recommendation	New Recommendation
13-Mar-2022	278	299.20	331.91	BUY	BUY
11-Nov-2022	238.50	333.38	299.20	BUY	BUY
24-Aug-2022	245.00	286.76	333.38	BUY	BUY

Company disclosures

Meristem or the analyst(s) responsible for the coverage may have financial or beneficial interest in securities or related investments discussed in this report, which could, unintentionally, affect the objectivity of this report. Material interests, which Meristem or the analyst(s) have with companies or in securities discussed in this report, are disclosed below:

Company	Disclosure
Dangote Cement Plc.	

- a. The analyst(s) hold(s) personal positions (directly or indirectly) in a class of the common equity securities of the company.
- b. The analyst responsible for this report, as indicated on the front page, is a board member, officer or director of the company
- c. Meristem beneficially owns 1% or more of the equity securities of the company
- d. Meristem has been the lead manager or co-lead manager of any publicly disclosed offer of securities of the company over the past 12 months.
- e. Meristem beneficially holds a major interest in the debt of the company
- f. Meristem has received compensation for investment banking activities from the company within the last 12 months
- g. Meristem intends to seek, or anticipates receipt of compensation for investment banking services from the company in the next 3 months
- h. The content of this research report has been communicated with the company, following which this research has been materially amended before its distribution
- i. The company is a client of the stock broking division of the Meristem group.
- j. The company is a client of the investment banking division of the Meristem group.
- k. Meristem is the registrar to the company.
- I. The company owns more than 5% of the issued share capital of Meristem
- m. Meristem has other financial or other material interest in the company.



March 13, 2022

Conflict of Interest

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests

Important Disclosure

For U.S. persons only: This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Meristem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, the company through its subsidiaries carries out stock broking, wealth management, trustees and registrars businesses which are regulated by the SEC and ICMR.

Copyright 2022 Meristem Securities Limited. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Meristem Securities Limited



March 13, 2022